English | Russian | Kazakh
ONCOLOGY, NUCLEAR MEDICINE AND TRANSPLANTOLOGY
Case Report
Jan 07, 2026 152 59

A Rare Case of Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome in a Patient after Liver Transplantation

Lyazzat Bekenkyzy Nur 1 * ,
Marzhan Zhanasbayeva 1,
Aibar Aginbay 1,
Kulpash Kaliaskarova 1,
Zhanat Spatayev 2,
Jamilya Saparbay 2,
Bairam Kochiyev 3
1 Department of Gastroenterology, National Research Oncology Center, Astana, Kazakhstan2 Department of Surgery, National Research Oncology Center, Astana, Kazakhstan3 Department of Radiology, National Research Oncology Center, Astana, Kazakhstan* Corresponding Author
Oncology, Nuclear Medicine and Transplantology, 2(1), 2026, onmt013, https://doi.org/10.63946/onmt/17728
Publication date: Jan 07, 2026
Full Text (PDF)

ABSTRACT

Posterior reversible encephalopathy syndrome (PRES) is a neurological condition characterized by seizures, encephalopathy, visual disturbances, and headache, often occurring in the context of hypertension and immunosuppressive therapy after solid organ transplantation. Although classically presenting with vasogenic edema in the parieto-occipital regions, atypical patterns may also occur. Here we report our experience with a case of cyclosporine-related PRES after liver transplant and summarize PRES clinical features through a literature review.
The case was a 53-year-old man who received a deceased donor liver transplant. His initial immunosuppressive therapy comprised cyclosporine/mycophenolate mofetil/prednisolone. Five months after transplantation, he was admitted to our center with altered mental status. The patient was diagnosed with PRES based on neurological symptoms and neuroimaging findings and recovered after switching from cyclosporine to everolimus. In addition, the lowering of blood pressure with drugs reported in the literature for use in PRES proved to be effective but challenging, requiring the use of multiple agents and only slowly leading to adequate control of hypertensive peaks. Nonetheless, hypertension management and supportive therapy allowed for a complete neurological recovery of the patient.
In conclusion, cyclosporine-associated PRES has a generally favorable prognosis with early diagnosis and prompt treatment, including altering or discontinuing CNIs and controlling blood pressure. CNI-associated PRES should be considered in patients exhibiting acute neurological symptoms after transplantation. Early diagnosis and immediate treatment are critical for a favorable prognosis.

KEYWORDS

PRES Patient Cyclosporine Encephalopathy

CITATION (Vancouver)

Nur LB, Zhanasbayeva M, Aginbay A, Kaliaskarova K, Spatayev Z, Saparbay J, et al. A Rare Case of Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome in a Patient after Liver Transplantation. Oncology, Nuclear Medicine and Transplantology. 2026;2(1):onmt013. https://doi.org/10.63946/onmt/17728
APA
Nur, L. B., Zhanasbayeva, M., Aginbay, A., Kaliaskarova, K., Spatayev, Z., Saparbay, J., & Kochiyev, B. (2026). A Rare Case of Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome in a Patient after Liver Transplantation. Oncology, Nuclear Medicine and Transplantology, 2(1), onmt013. https://doi.org/10.63946/onmt/17728
Harvard
Nur, L. B., Zhanasbayeva, M., Aginbay, A., Kaliaskarova, K., Spatayev, Z., Saparbay, J., and Kochiyev, B. (2026). A Rare Case of Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome in a Patient after Liver Transplantation. Oncology, Nuclear Medicine and Transplantology, 2(1), onmt013. https://doi.org/10.63946/onmt/17728
AMA
Nur LB, Zhanasbayeva M, Aginbay A, et al. A Rare Case of Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome in a Patient after Liver Transplantation. Oncology, Nuclear Medicine and Transplantology. 2026;2(1), onmt013. https://doi.org/10.63946/onmt/17728
Chicago
Nur, Lyazzat Bekenkyzy, Marzhan Zhanasbayeva, Aibar Aginbay, Kulpash Kaliaskarova, Zhanat Spatayev, Jamilya Saparbay, and Bairam Kochiyev. "A Rare Case of Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome in a Patient after Liver Transplantation". Oncology, Nuclear Medicine and Transplantology 2026 2 no. 1 (2026): onmt013. https://doi.org/10.63946/onmt/17728
MLA
Nur, Lyazzat Bekenkyzy et al. "A Rare Case of Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome in a Patient after Liver Transplantation". Oncology, Nuclear Medicine and Transplantology, vol. 2, no. 1, 2026, onmt013. https://doi.org/10.63946/onmt/17728

REFERENCES

  1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494–500.
  2. Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol. 2017 Aug;264(8):1608-1616. doi:10.1007/s00415-016-8377-8
  3. Bartynski WS, Tan HP, Boardman JF, Shapiro R. Posterior reversible encephalopathy syndrome after solid organ transplantation. AJNR Am J Neuroradiol. 2008;29(5):924–930. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128592/
  4. Cruz RJ Jr, DiMartini A, Akhavanheidari M, Iacovoni N, Boardman JF, Donaldson J, et al. Posterior reversible encephalopathy syndrome in liver transplant patients: clinical presentation, risk factors and initial management. Am J Transplant. 2012;12(8):2228–2236.
  5. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914–925. doi:10.1016/S1474-4422(15)00111-8
  6. Chen S, Hu J, Xu L, Brandon D, Yu J, Zhang J. Posterior reversible encephalopathy syndrome after transplantation: a review. Mol Neurobiol. 2016;53(10):6897–6909.
  7. Lunardi N, Saraceni E, Boccagni P, Gringeri E, Barbieri S, Rossi S, et al. Posterior reversible encephalopathy syndrome in the intensive care unit after liver transplant: a comparison of our experience with the existing literature. Minerva Anestesiol. 2012;78(7):847–850. Available from: https://pubmed.ncbi.nlm.nih.gov/21701444/
  8. Geocadin RG. Posterior Reversible Encephalopathy Syndrome. N Engl J Med. 2023;388(23):2171-2178.
  9. Gong Y. Calcineurin inhibitors-related posterior reversible encephalopathy syndrome in liver transplant recipients: Three case reports and review of literature. World J Hepatol. 2024;16(9):1297-1307. doi:10.4254/wjh.v16.i9.1297
  10. Alshami A, Al-Bayati A, Douedi S, Hossain MA, Patel S, Asif A. Clinical characteristics and outcomes of patients admitted to hospitals for posterior reversible encephalopathy syndrome: a retrospective cohort study. BMC Neurol. 2021;21(1):107. doi:10.1186/s12883-021-02143-6
  11. Yoon SD, Cho BM, Oh SM, Park SH, Jang IB, Lee JY. Clinical and radiological spectrum of posterior reversible encephalopathy syndrome. J Cerebrovasc Endovasc Neurosurg. 2013;15(3):206–13. doi:10.7461/jcen.2013.15.3.206
  12. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85(5):427–32. doi:10.4065/mcp.2009.0590
  13. Lee VH, Wijdicks EFM, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205–10. doi:10.1001/archneurol.2007.46
  14. Gewirtz AN, Gao V, Parauda SC, Robbins MS. Posterior Reversible Encephalopathy Syndrome. Curr Pain Headache Rep. 2021;25(3):19. doi:10.1007/s11916-020-00932-1
  15. Siebert E, Bohner G, Liebig T, Endres M, Liman TG. Factors associated with fatal outcome in posterior reversible encephalopathy syndrome: a retrospective analysis of the Berlin PRES study. J Neurol. 2017;264(2):237-242.
  16. Kumar SS, Mashour GA, Picton P. Neurologic Considerations and Complications Related to Liver Transplantation. Anesthesiology. 2018;128(5):1008-1014.
  17. Song T, Rao Z, Tan Q, Qiu Y, Liu J, Huang Z, et al. Calcineurin Inhibitors Associated Posterior Reversible Encephalopathy Syndrome in Solid Organ Transplantation: Report of 2 Cases and Literature Review. Medicine (Baltimore). 2016;95(14):e3173.
  18. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29(6):1036–1042. doi:10.3174/ajnr.A0928
  19. Heidenhain C, Puhl G, Neuhaus P. Late fulminant posterior reversible encephalopathy syndrome after liver transplant. Exp Clin Transplant. 2009;7(3):180–183.
  20. Rajakumar A, Paulin S, Devarajan D, Jothimani D, Subramanian S, Kalyanasundaram S, et al. An Unusual Presentation of Posterior Reversible Encephalopathy Syndrome Following Liver Transplantation. Transplant Direct. 2022;8(2):e1269. doi:10.1097/TXD.0000000000001269
  21. Legriel S, Schraub O, Azoulay E, Hantson P, Magalhaes E, Coquet I, et al. Determinants of recovery from severe posterior reversible encephalopathy syndrome. PLoS One. 2012;7(9):e44534. doi:10.1371/journal.pone.0044534
  22. Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008;29(6):1043–1049.
  23. Wu Q, Marescaux C, Wolff V, Jeung MY, Kessler R, Lauer V, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. Eur Neurol. 2010;64(3):169–177. doi:10.1159/000319032
  24. Zhou F, Costa AF, McLeod M. Late presentation of posterior reversible encephalopathy syndrome following liver transplantation in the setting of tacrolimus and cannabis use. Can Liver J. 2022;5(1):91-95. doi:10.3138/canlivj-2021-0017
  25. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007;28(7):1320-1327.
  26. Singhal AB. Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome as syndromes of cerebrovascular dysregulation. Continuum (Minneap Minn). 2021;27(5):1301-1320.
  27. Granata G, Greco A, Iannella G, Granata M, Manno A, Savastano E, et al. Posterior reversible encephalopathy syndrome—insight into pathogenesis, clinical variants and treatment approaches. Autoimmun Rev. 2015;14(9):830–836. doi:10.1016/j.autrev.2015.05.006
  28. Harirchian MH, Ghaffarpour M, Tabaeizadeh M, Fatehi F, Pakdaman H, Amir Ahmadi M, et al. Immunosuppressive drugs, an emerging cause of posterior reversible encephalopathy syndrome: case series. J Stroke Cerebrovasc Dis. 2015;24(7):e191–e195.
  29. Dzudie A, Boissonnat P, Roussoulieres A, Cazorla C, Bastien O, Ninet J, et al. Cyclosporine-related posterior reversible encephalopathy syndrome after heart transplantation: should we withdraw or reduce cyclosporin?: case reports. Transplant Proc. 2009;41(2):716–720.
  30. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115.

LICENSE

Creative Commons License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.